ערך בספרים למניה: ImmunoPrecise (IPA)

ImmunoPrecise Antibodies (IPA) effectively integrates AI algorithms with biotech for the rapid selection of therapeutic antibodies, eliminating price wars with conventional laboratories. The target book value per share demonstrates asset resilience, with the current level sitting around 0.37. The business's sustainability is supported by virtual testing that reduces chemical waste, while database cybersecurity ensures ethical management.

For ImmunoPrecise Antibodies (IPA), which is scaling AI-driven antibody development via the BioStrand platform, the book value per share trend reflects the efficiency of capitalizing intellectual assets and libraries. This indicator is calculated as the difference between total assets and liabilities divided by the number of shares outstanding, allowing investors to track the real value of the company's assets and identify hidden equity dilution.